{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:11:56Z","timestamp":1783469516168,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.clinthera.2015.11.013","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T22:17:49Z","timestamp":1450822669000},"page":"4-15","source":"Crossref","is-referenced-by-count":10,"title":["Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct00868452","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00868699","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sunny","family":"Chapel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Cucchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.11.013_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.clinthera.2015.11.013_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","article-title":"A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder","volume":"60","author":"Judd","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.clinthera.2015.11.013_bib5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4088\/JCP.v65n1109","article-title":"Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample","volume":"65","author":"Calabrese","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1399-5618.2007.00430.x","article-title":"Disability and its treatment in bipolar disorder patients","volume":"9","author":"Huxley","year":"2007","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.clinthera.2015.11.013_bib7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","article-title":"Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study","volume":"62","author":"Judd","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1176\/ajp.2006.163.9.1561","article-title":"Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers","volume":"163","author":"Kessler","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-1781(97)00109-1","article-title":"Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania","volume":"73","author":"Dilsaver","year":"1997","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.clinthera.2015.11.013_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4088\/JCP.v64n0503","article-title":"Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network","volume":"64","author":"Leverich","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2015.11.013_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.jcp.0000167791.70664.d4","article-title":"Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments","volume":"25","author":"Lipkovich","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2015.11.013_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.2009.44","article-title":"Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia","volume":"86","author":"Friberg","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.11.013_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-244X-8-3","article-title":"Evaluating dose response from flexible dose clinical trials","volume":"8","author":"Lipkovich","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1067\/mcp.2000.110975","article-title":"Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model","volume":"68","author":"Kimko","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.11.013_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JCP.0b013e3182a4ee2c","article-title":"Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale","volume":"33","author":"Pilla Reddy","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2015.11.013_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2013.02.010","article-title":"Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score","volume":"146","author":"Pilla Reddy","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2015.11.013_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/FTD.0000000000000014","article-title":"Population pharmacokinetic\/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia","volume":"36","author":"Shang","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2015.11.013_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1192\/bjp.148.5.599","article-title":"Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales","volume":"148","author":"Snaith","year":"1986","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.11.013_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2015.11.013_bib24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079908X291958","article-title":"The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach","volume":"24","author":"Duru","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2015.11.013_bib25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/clpt.2011.322","article-title":"Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression","volume":"91","author":"Russu","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.11.013_bib26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.npp.1300059","article-title":"Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports","volume":"28","author":"Khan","year":"2003","journal-title":"Neuropsychopharmacology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815012977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815012977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T17:52:33Z","timestamp":1537120353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815012977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0149291815012977"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.11.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}